Abstract
Cytochrome P450 (CYP450) enzymes have the capability of playing key metabolic roles in several aspects of cancer as a consequence of their unusually broad substrate specificities. CYP450 are also prominent players in the metabolism of anticancer therapeutic drugs, enhancing or diminishing the efficacy of the drugs depending on whether the drug or its metabolites are efficacious. As CYP450 enzymes are also found in lung tissue, lung metabolism can be of importance to the bioactivation of some anticancer agents. The presence of individual forms of CYP450 has been investigated in lung tumor to determine whether intra-tumor metabolism of anticancer agents by CYP450 could occur and thus influence the response of tumor to these agents. Differences in drug metabolism between normal and cancerous lung tissue have been shown to exist, therefore; the variable expression of CYP450 between tumor and normal tissue can provide a basis for selective sensitivity of tissue to anticancer drugs, thereby localizing drug actions to tumor. This review gives a detailed picture of the expression of CYP450 in lung tumor and the role of this enzyme in lung tumor in the fate of anticancer drugs.
Keywords: anticancer drugs, cytochrome p450, drug metabolizing enzymes, cancer, lung, tumor
Current Drug Metabolism
Title: Expression of Cytochrome P450 in Lung Tumor
Volume: 5 Issue: 2
Author(s): Negar Gharavi and Ayman O.S. El-Kadi
Affiliation:
Keywords: anticancer drugs, cytochrome p450, drug metabolizing enzymes, cancer, lung, tumor
Abstract: Cytochrome P450 (CYP450) enzymes have the capability of playing key metabolic roles in several aspects of cancer as a consequence of their unusually broad substrate specificities. CYP450 are also prominent players in the metabolism of anticancer therapeutic drugs, enhancing or diminishing the efficacy of the drugs depending on whether the drug or its metabolites are efficacious. As CYP450 enzymes are also found in lung tissue, lung metabolism can be of importance to the bioactivation of some anticancer agents. The presence of individual forms of CYP450 has been investigated in lung tumor to determine whether intra-tumor metabolism of anticancer agents by CYP450 could occur and thus influence the response of tumor to these agents. Differences in drug metabolism between normal and cancerous lung tissue have been shown to exist, therefore; the variable expression of CYP450 between tumor and normal tissue can provide a basis for selective sensitivity of tissue to anticancer drugs, thereby localizing drug actions to tumor. This review gives a detailed picture of the expression of CYP450 in lung tumor and the role of this enzyme in lung tumor in the fate of anticancer drugs.
Export Options
About this article
Cite this article as:
Gharavi Negar and El-Kadi O.S. Ayman, Expression of Cytochrome P450 in Lung Tumor, Current Drug Metabolism 2004; 5 (2) . https://dx.doi.org/10.2174/1389200043489045
DOI https://dx.doi.org/10.2174/1389200043489045 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry A Cohort Study and Meta-Analysis between Histopathological Classification and Prognosis of Gastric Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Screening of NO Inhibitor Release Activity from Soft Coral Extracts Origin Palu Bay, Central Sulawesi, Indonesia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Apoptotic Pathways in the Pathogenesis of Pemphigus: Targets for New Therapies
Current Pharmaceutical Biotechnology Development of 96-microwell Plate Assay with Fluorescence Reader and HPLC Method with Fluorescence Detection for High-throughput Analysis of Linifanib in its Bulk and Dosage Forms
Current Pharmaceutical Analysis Diverse Roles of GADD45α in Stress Signaling
Current Protein & Peptide Science Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation
Current Cancer Drug Targets Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status
Current Cancer Drug Targets Growth Responses Following a Single Intra-Muscular hGH Plasmid Administration Compared to Daily Injections of hGH in Dwarf Mice
Current Gene Therapy MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Putative Mechanisms of Viral Transmission and Molecular Dysregulation of Mammary Epithelial Cells by Human Papillomavirus: Implications for Breast Cancer
Current Molecular Medicine